NanoRepro AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNGRF research report →
About the company
NanoRepro AG specializes in the conception, production, and global distribution of swift diagnostic assays and nutritional supplements. These offerings cater to both individual consumers and healthcare professionals, operating primarily from Germany. Their diagnostic portfolio encompasses diverse health sectors, including reproductive health, general disease identification, and the detection of food sensitivities, allergic reactions, and infectious pathogens.
- CEO
- Lisa Jungst
- IPO
- 2021
- Employees
- 17
- HQ
- Marburg, DE
Price Chart
- Market Cap
- $164.30M
- P/E
- -15.80
- P/S
- 5.27
- P/B
- 0.73
- EV/EBITDA
- -9.22
- Div Yield
- 0.00%
- Gross Margin
- 43.17%
- Op Margin
- -44.77%
- Net Margin
- -33.37%
- ROE
- -4.57%
- ROIC
- -6.14%
- Revenue
- $4.65M · 43.15%
- Net Income
- $-2,045,757.4 · 56.34%
- EPS
- $-0.16 · 56.76%
- Op Income
- $-3,623,835
- FCF YoY
- 192.15%
- 52W High
- $12.76
- 52W Low
- $12.76
- 50D MA
- $12.76
- 200D MA
- $12.76
- Beta
- -2.94
- Avg Volume
- 0
Get TickerSpark's AI analysis on NNGRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NNGRF coverage
Recent articles, reports, and earnings notes.
No research on NNGRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NNGRF report →Similar companies
Peers in the same neighborhood.